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Background: The progressive nature of glaucoma and its growing incidence make its therapy an important target
for research. The role of oxidative damage in the pathogenesis of glaucoma makes antioxidants such as saffron
extract an attractive target for potential clinical use. Herein, we evaluate the effect of aqueous saffron extract on
intraocular pressure (IOP) in eyes with primary open-angle glaucoma (POAG).
Methods: Thirty-four eyes of 34 clinically stable POAG patients receiving treatment with timolol and dorzolamide
eye drops were enrolled in this prospective, comparative, randomized interventional pilot study. Eligible subjects
were randomized to receive 30 mg/day aqueous saffron extract orally (17 subjects, 17 eyes) or placebo (17 subjects,
17 eyes) for one month as an adjunct to timolol and dorzolamide. Following treatment, both study groups entered
a one-month wash-out period. The main outcome measure was IOP during treatment and after the wash-out period.
Results: Mean baseline IOP was 12.9 ± 3.7 versus 14.0 ± 2.5 mmHg in the saffron and control groups, respectively
(p = 0.31). After three weeks of treatment, IOP was significantly decreased to 10.9 ± 3.3 mmHg in the saffron group
as compared to 13.5 ± 2.3 mmHg in the control group (p = 0.013). At four weeks, IOP was still significantly lower in the
saffron group (10.6 ± 3.0 versus 13.8 ± 2.2 mmHg, p = 0.001). At the end of the wash-out period, IOP was 12.9 ± 3.0 in
the saffron group versus 14.2 ± 2.0 mmHg in the control group (p = 0.175). None of the patients experienced side
effects during the study and wash-out period.
Conclusions: Oral aqueous saffron extract seems to exert an ocular hypotensive effect in primary open-angle glaucoma.
This effect became evident after three weeks of therapy.
The current study was registered at the International Clinical Trials Registry Platform (ICTRP) as IRCT201201278832N1.
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Glaucoma is the most common progressive optic neur-
opathy [1] and the most important risk factor for devel-
opment of glaucomatous optic neuropathy is elevated
intraocular pressure (IOP) [2]. Abnormal resistance to
the outflow of aqueous humor through the trabecular
meshwork (TM) is the key pathogenic factor in primary
open angle glaucoma (POAG) [3].
Oxidative stress has been suggested to play a role in
POAG and the trabecular meshwork is the most sensi-
tive anterior chamber structure to oxidative stress [4-8].* Correspondence: mhbonyadi@yahoo.com
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article, unless otherwise stated.The important role of oxidative damage in the pathogen-
esis of POAG makes it an important therapeutic target
and antioxidative therapy has been shown to entail an
ocular hypotensive effect against dexamethasone induced
IOP elevation [9].
Saffron, derived from the pistils of Crocus sativus, con-
tains high concentrations of crocin and crocetin, which
are carotenoid derivatives. This plant belongs to the
Iridaceae family. Multiple divalent carbon bonds in saf-
fron compounds confer its powerful radical scavenging,
antioxidative and anti-tumor properties [10-13]. Saffron
has been widely used for many years in traditional Asian
medicine and in Persian medicine in particular to treat
depression [14].
The purpose of this pilot study was to investigate
the possible ocular hypotensive effect of high dose oralMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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our knowledge this is the first report on this subject.
Methods
Setting
This randomized study was performed at the depart-
ment of Ophthalmology, 22nd of Bahman Hospital,
Gonabad, Iran in collaboration with the Ophthalmic Re-
search Center, Shahid Beheshti University of Medical
Sciences, Tehran, Iran. Consecutive POAG patients were
recruited from the ophthalmology clinic and assessed for
eligibility. Patients who met the inclusion criteria en-
tered our pre-study observation period (February 2012-
March 2013) during which stability of glaucoma was
confirmed (for at least 6 months) while the subjects were
receiving topical medications. Eventually 50 eyes of the
same number of stable POAG patients were enrolled for
intervention (April 2013). This study was registered at the
International Clinical Trials Registry Platform (ICTRP) as
IRCT201201278832N1.
Inclusion and exclusion criteria
Patients with POAG older than 50 years of age who
were under treatment with topical timolol 0.5% twice
daily and dorzolamide 2% three times daily and were
judged to have stable glaucoma control for at least
6 months based on a series of visual field and optic
nerve head examinations were considered for enrollment
as stated earlier.
Exclusion criteria consisted of prior intraocular sur-
gery, glaucoma other than POAG, visual acuity less than
5/10, advanced glaucoma (equal or more than 90 per-
cent vertical cupping), history of saffron hypersensitivity,
intestinal absorption abnormalities and smoking. In the
case of bilateral involvement, only the right eye was in-
cluded. None of the patients were taking medications
(e.g., chloroquine) known to interfere with carotenoid
absorption. Patients with central corneal thickness (CCT)
values less than 500 or more than 540 microns were also
excluded.
During the study period, enrolled subjects would be
eliminated from the study if they failed to attend regular
follow-up sessions, maintain a regular regimen of topical
glaucoma medication or saffron/placebo, or consumed a
systemic medication with a known effect on IOP.
Informed consent and ethical issues
The study adhered to the tenets of the Declaration of
Helsinki and was approved by the Ethics Committee of
Gonabad Medical University. Prior to enrollment, poten-
tial advantages and risks of therapy were discussed with
the patients and written informed consent was obtained
from all participants. Consent forms contained possible
side effects of high dose oral saffron including anxiety,appetite changes, nausea, headache, dry mouth, consti-
pation, allergic reactions and jaundice.
Pre-intervention evaluations and follow-up
All participants underwent a detailed baseline ophthalmic
examination including slitlamp biomicroscopy, gonio-
scopy, dilated lens and optic nerve head examination and
IOP measurement using Goldmann applanation tonome-
try in addition to corneal pachymetry (OcuScan, Alcon
Laboratories, Irvine, California, USA). For all cases and
control patients, IOP was measured between 9 to 10 AM
at baseline, at 1, 3 and 4 weeks following initiation of
intervention, and at the end of the wash-out period.The
list of side effects as mentioned in Informed Consent and
Ethical Issues section was checked in each session. Every
patient was asked and examined according to mentioned
list and also asked about any other symptom in each
exam session to reveal possible side effects.
Randomization and masking
Patients were randomly assigned to the saffron regimen or
placebo (simple randomization in two parallel groups).
Both capsules were identical regarding shape, color and
size. Participants were kept masked to the intervention and
outcome measures, the ophthalmologist evaluating the
outcome measure and the statistician involved in data ana-
lysis were also unaware of patient identity and study group.
Eligible patients were introduced to our secretary who ran-
domly selected one sealed, opaque envelope with 28 cap-
sules containing saffron extract or placebo for each patient
according to the randomization sheet.
The allocated group of each patient was registered and
concealed up to the end of the study period and revealed
only after final data analysis.
Intervention
Crocus sativus L. stigmas were collected from Gonabad
(East Sorkhfam Saffron Co. Gonabad, Khorasan, Iran).
Using the maceration method, saffron capsules containing
thirty milligrams of the concentrated powder were pre-
pared [12]. Starch powder was used with the same weight
inside identical capsules for the placebo group. Capsule
preparation for both study groups was performed by
Genaati pharmacy, Gonabad, Khorasan, Iran. Study sub-
jects were randomly assigned to oral saffron extract
(30 mg/day) versus placebo for a one month period while
topical timolol and dorzolamide were continued through-
out the randomization process. Following treatment, both
groups entered a one-month wash-out period, during
which all patients stopped ingestion of saffron/placebo cap-
sules but continued their glaucoma medications as before.
At the end of the wash-out period IOP measurement
(using Goldmann applanation tonometry) and ophthalmo-
logic evaluation (by a masked ophthalmologist MHJB) was
Table 1 Baseline characteristics of patients
Saffron group Placebo group
Male 10 11 pβ = 0.72
Female 7 6
Age 66.3 ± 9.5 67.6 ± 8.3 p* = 0.69
CCT 518 ± 13.1 519 ± 14.7 p* = 0.98
vertical cup disc ratio 0.68 ± 0.10 0.71 ± 0.08 P® = 0.33
VF MD -5.47 ± 1.5 -4.99 ± 1.9 p* = 0.416
CCT: central corneal thickness, VF MD: visual field defect mean deviation.
β: based on Chi-square test.
*: based on t-test.
®: based on Mann-whitney test.
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about and examined for possible side effects of saffron.
Outcome measures
The main outcome measure of the study was IOP.
Statistical methods
In this pilot RCT we enrolled 25 POAG patients in each
group. Means and standard deviations were used for
description of study parameters. Statistical analysis was
performed by a biostatistician using SPSS software
version 17.0 (SPSS Co., Chicago, IL, USA) who was un-
aware of study group identity. Mean CCT and mean
IOP differences between study and control groups were
analyzed individually by independent student t-test. The
Mann-whitney test was employed to compare mean verti-
cal cup disc ratio between the two groups because of non-
normal distribution of this variable.
Results
Initially 50 subjects fulfilled the eligibility criteria and
were enrolled but a total of 16 subjects were eliminated
from the study. The excluded patients in the saffron
group consisted of 5 patients with incomplete follow-up
and 3 patients who used their capsules irregularly. Ex-
cluded patients in the placebo group consisted of 6 patients
with incomplete follow-up, one patient with irregular cap-
sule consumption and another subject who started a sys-
temic B blocker during the study period.
Eventually a total of 34 randomized subjects including
17 patients (7 female and 10 male individuals) in the saf-
fron group and 17 other patients (6 female and 11male
individuals) in the placebo group completed all follow-
up sessions. None of the enrolled patients experienced
side effects of saffron during the study or the wash-out
period.
Mean patient age was 66.3 ± 9.5 (range 51 to 79) years
versus 67.6 ± 8.3 (range 53 to 77) years in the saffron
and placebo groups, respectively (p = 0.69). CCT was
518 ± 13.1 microns in the saffron group versus 519 ± 14.7
microns in the control group (p = 0.98). Mean vertical
cup disc ratio was 0.68 ± 0.10 in the saffron group and
0.71 ± 0.08 in the placebo group (P = 0.33). Mean baseline
IOP was 12.9 ± 3.7 (range 7 to 19) mmHg in the saffron
group and 14.0 ± 2.5 (range 9 to 18) mmHg in the control
group (95% confidence interval [CI] for mean difference:-
1.1 ± 2.2 mmHg, p = 0.31).Baseline features of enrolled pa-
tients are summarized in Table 1.
One week after intervention, IOP was 12.0 ± 3.3 (range 8
to 17) mmHg in the saffron group versus 13.6 ± 2.6 (range
9 to 18) mmHg in the control group (95% CI for mean dif-
ference: -1.65 ± 2.05 mmHg, p = 0.114). At three weeks,
IOP reached 10.9 ± 3.3 (range 6 to 17) mmHg in the
saffron group versus 13.5 ± 2.3 (range 9 to 17) mmHg inthe control group (95% CI for mean difference; -2.6 ±
2.00 mmHg, p = 0.013). At four weeks IOP was 10.6 ± 3.0
(range 6 to 16) mmHg in the saffron group versus 13.8 ±
2.2 (range 10 to17) mmHg in the control group (95% CI
for mean difference: -3.25 ± 1.85 mmHg, p = 0.001). At
the end of the wash-out period, IOP was 12.9 ± 3.0
(range 8 to 18) mmHg in the saffron group and 14.2 ± 2.0
(range 11 to 18) mmHg in the control group (95% CI for
mean difference: -1.20 ± 1.80 mmHg, p = 0.175) (Figure 1).
Discussion
Saffron has been widely used for many years in trad-
itional Persian medicine to treat depression [14] and its
crude extract has recently been shown to prevent tumor
formation [13] and selenite-induced cataracts [15].
Saffron belongs to the Iridaceae family and its variants
are not of the same quality and strength. Strength is re-
lated to several factors including the amount of styles
picked along with the red stigma. Grades of Iranian saf-
fron are: “Sargol” (red stigma tips only, premium grade),
“Pushal” or “Pushali” (red stigmas plus some yellow style,
lower strength), “Bunch” saffron (red stigmas plus large
amounts of yellow style, presented in a tiny bundle) and
“Konge” (yellow style only, claimed to have aroma but with
very little, if any, coloring potential). In our study only
premium Sargol grade fresh saffron was used by East
Sorkhfam Saffron Co. for capsule preparation.
Antioxidants, ingested through diet and supplements,
have been shown to be beneficial in terms of reducing
the risk of multiple ocular diseases including age-related
macular degeneration (based on the Age-Related Eye
Disease Study, AREDS) [16] and cataracts [17].
A number of studies have strongly suggested the role
of oxidative stress in POAG [4-8,18,19] and there is in-
creasing evidence that oxidative stress also has an im-
portant role in progression of glaucomatous damage
[20]. The TM is the most sensitive anterior chamber tis-
sue to oxidative stress. [4] Light induced formation of
oxidative radicals may target the TM and contribute
to the pathogenesis of glaucoma [4,21]. Disturbed TM
Figure 1 Mean IOP change during 4 weeks after initiation of saffron or placebo in addition to conventional timolol and dorzolamide
therapy in primary open angle glaucoma and after one month of wash-out (Arrows indicate where mean IOP levels were significantly
different between the two study groups).
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lar loss and structural alterations in its extracellular
matrix resulting in impaired aqueous humor outflow
and thereby an increase in IOP [22,23]. In addition to the
observed effect of saffron extract regarding IOP reduction,
its possible role as antioxidant-neuroprotective agent
[24] may further provide protection against glaucomat-
ous optic neuropathy.
Other agents with antioxidant properties have been
used for treatment of glaucoma. Ginkgo biloba, similar
to saffron, has antiapoptotic and antioxidant capacities
[25,26] and has demonstrated desirable effects on steroid-
induced ocular hypertension. In a rabbit model, Jia et al
[9] demonstrated that topical Ginkgo biloba extract 4
times daily could suppress dexamethasone induced IOP
elevation after 14 days of treatment. In another in vitro
study, use of vitamin E as an antioxidant agent was shown
to reduce the production of reactive oxygen species and
inhibit cell death in TM cell cultures derived from glau-
comatous patients [27]. Oxidative stress, in vitro, has been
shown to result in mitochondrial and cellular dysfunction
in the TM resulting in trabecular cell apoptosis [27,28].
Therefore antioxidants seems to exert both a short term
effect in terms of rehabilitating damaged but still func-
tional TM, and a long term benefit by reducing apoptosis.
The ocular hypotensive effect of saffron extract in our
study could be due to the short term effect.
The current study showed that oral aqueous saffron
extract had an ocular hypotensive effect in POAG pa-
tients receiving treatment with timolol and dorzolamide.This effect became evident three weeks after therapy and
was accentuated at four weeks.
Employing a washout period, IOP returned to pre-
treatment levels after one month of discontinuation.
(Figure 1) The observed reduction in IOP may be due to
antioxidant carotenoid derivatives present in saffron ex-
tract, mainly crocin and crocetin.
In a recently published epidemiologic study in an
African-American population it has been shown that
carotenoids seem to display a protective effect against
glaucoma [29]. In contrast, Kang et al reported no asso-
ciation between higher intake of various antioxidants
and glaucoma [30]. Such differences in the correlation
between glaucoma risk and carotenoids may be due to
differences in study population, age, eating habits and
food preparation methods. It has also been shown that
genetic predisposition to oxidative stress may determine
susceptibility to glaucoma [18] and the response to anti-
oxidants as ocular hypotensive agents seems to be influ-
enced by genetic background.
In the current study, we selected POAG patients
whose IOP was controlled with two topical medications.
We assume that regarding the role of oxidative damage
in the pathogenesis of glaucoma, our results may be
generalizable for POAG of different severity levels and
possibly other types of glaucoma. Although our observa-
tions are promising, there are limitations which have to
be kept in mind; regular high dose crude oral saffron
may not be a feasible treatment option for glaucoma
while small sample size and short term follow-up in this
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larger sample size and longer follow-up on different types
glaucoma with varying severity could verify our results.
Saffron shown to have a very low toxicity in in vivo
studies and daily doses of up to 1.5 gr are thought to be
safe. Toxic effects are reported with 5 gr and above, with
a lethal dose of approximately 20 gr and it could induce
abortion in doses >10 gr. The colored constituents may
accumulate in sclera, skin and may thus mimic icteric
complaints. Nausea was described in doses between 1.2 gr
and 2 gr followed by vomiting, diarrhea and bleeding [31].
Since the dose shown to be efficacious in depression trials
corresponded to approximately 30 mg of saffron, there is a
large safety margin [32]”.
Conclusions
In summary, this pilot study revealed an ocular hypo-
tensive effect from high dose oral aqueous saffron ex-
tract in POAG patients when the supplement was added
to conventional timolol and dorzolamide treatment. To
the best of our knowledge this is the first study reporting
the effect of saffron on IOP. This early ocular hypotensive
effect, similar to its influence in early age-related macular
degeneration, [33] indicates that high dose systemic saffron
may entail a therapeutic effect.
It must be kept in mind that high dose antioxidants
may have paradoxical pro-oxidative effects exemplified
by an increased risk of lung cancer with higher dietary
intake of carotene [34,35]. Whether topically adminis-
tered saffron compounds may also reduce IOP, requires
further studies. Reaching a topical saffron formulation
necessitates preparing a topical solution with reduced
coloring capacity and minimal sensitizing side effects.
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